Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ: AKRO )

29.34 +0.94 (+3.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q2 2024
AKRO stock results show that Akero Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's Q2 FY24 earnings report on August 8 will include a pre-tax IPR&D charge of... 
Via Benzinga
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. 
Via Investor's Business Daily
Akero Therapeutics: Q4 Earnings Insights
Via Benzinga
11 Analysts Have This to Say About Akero Therapeutics
Via Benzinga
Akero Therapeutics: Q3 Earnings Insights
Via Benzinga
The Week Ahead: What's Next
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024
AKRO stock results show that Akero Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
Via Benzinga
Why Akero Therapeutics Shares Are Slumping This Week
Akero's lead therapy fell short of its goals in a phase 2b trial to treat NASH. 
Via The Motley Fool
Analyst Ratings for Akero Therapeutics
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Akero Therapeutics' Stock Is Soaring Monday - Here's Why
Akero Therapeutics success in HARMONY Phase 2b study for efruxifermin. EFX demonstrated sustained efficacy and well-tolerance, marking a major milestone in liver disease treatment. 
Via Benzinga
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing. 
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Super Micro Computer, Deckers Outdoor And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 50 points on Monday. Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) rose sharply in today’s pre-market... 
Via Benzinga
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance... 
Via Benzinga
E2open, Sharecare And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded higher this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward
Tuesday, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Wegovy Maker Novo Nordisk, Akero Therapeutics, Eli Lilly, Athena Consumer Acquisition, Tesla: Why These 5 Stocks Are Trending Today
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 130 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in... 
Via Benzinga
Why Shares of 89bio Plummeted on Tuesday
So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors. 
Via The Motley Fool
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.